On December 15, 2025, Mr. Huang Bisheng, Chairman of Zhejiang Tianyuan Biotechnology Co., Ltd., led a delegation to Hainan Medical University for a symposium. Both parties reached a consensus on clinical project cooperation in areas including stem cell medical technology, drug R&D, and reagent development.

      On December 16, Chairman Huang and his delegation visited the Ningbo Chamber of Commerce in Hainan Province for exchange and inspection. On the same day, witnessed by the Ningbo Chamber of Commerce in Hainan Province, Tianyuan Biotech (Hainan) Co., Ltd. was officially inaugurated. This pivotal move secures a first-mover advantage for the company’s industrial deployment in the pilot zone of the Hainan Free Trade Port. Tianyuan Biotech (Hainan) Co., Ltd. will focus on establishing platforms for metabolic immunity, medical testing, and cell quality control locally, providing robust infrastructure support for the company’s future business expansion.

      That afternoon, the Tianyuan Biotech team arrived at the Management Committee of Haikou National Hi-tech Industrial Development Zone. Dr. Liu Guangcheng, Director of the company’s Cell Laboratory, elaborated on Tianyuan Biotech’s technological advantages in cell R&D, covering advanced cell culture processes, unique cell seed bank construction, and frontier exploration in biomedical technology. Ms. Ning Yuhui, Member of the Working Committee and Deputy Director of the Management Committee of Haikou Hi-tech Zone, highly affirmed Tianyuan Biotech’s technical strength and expressed full support for the company’s development.

      The establishment of Tianyuan Biotech (Hainan) Co., Ltd. marks a significant milestone in Tianyuan Biotech’s strategic deployment in the biopharmaceutical industry. Leveraging the liberalization and facilitation policy advantages of the Hainan Free Trade Port, Tianyuan Biotech has implemented a dual industrial layout across mainland China and Hainan. The implementation of this strategy demonstrates its profound insight into and grasp of industry development trends. Taking this as an opportunity, Tianyuan Biotech will embark on a new journey, contributing to the innovative development of the biopharmaceutical industry and steadily advancing towards its goal of becoming an industry leader.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Tumor Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.